Guardant Health shares are trading lower after FDA staff in a briefing said the company's test may fail to detect some types of advanced adenomas in patients.
Portfolio Pulse from Benzinga Newsdesk
Guardant Health shares are trading lower after FDA staff indicated that the company's test may fail to detect some types of advanced adenomas in patients.
May 21, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Guardant Health shares are trading lower following an FDA briefing that raised concerns about the company's test potentially failing to detect some types of advanced adenomas in patients.
The FDA's concerns about the effectiveness of Guardant Health's test are likely to negatively impact investor confidence and the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100